(CercleFinance.com) – Currently in the midst of a strategic redeployment, Quantum Genomics announced last night that it had entered into advanced discussions with a company whose skills are complementary to its own.
The biopharmaceutical company had already announced, at the end of 2022, that it had entered into discussions with several companies in order to build a “new business project”.
Its efforts have focused on projects already in the commercialization phase or close to market launch, operating in high volume markets and with high technological value in the healthcare sector.
As part of the discussions with its potential partner, the objective is to reach a short-term agreement, said Quantum in a press release.
The company explains that it has restructured and significantly lowered its fixed cost structure in order to begin its new start ‘under the best conditions’.
At the end of October, the company announced negative results from its phase III study, which prompted it to take the decision to stop another phase II study, as well as all related developments.
Following the formalization of these discussions, the Quantum title climbed more than 70% on Thursday on the Paris Stock Exchange.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
